{"schema_version":"secwatch.filing_event.v1","accession":"0001285550-22-000076","form_type":"8-K","ticker":"CLPT","cik":"0001285550","company_name":"ClearPoint Neuro, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.002670+00:00","generated_at":"2026-06-22T02:58:54.726372+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ClearPoint Neuro Q3 revenue $5.1M (+13% YoY); reaffirms FY2022 guidance","bullets":["Revenue of $5.1M, up 13% YoY; gross margin improved to 72% from 66%.","Cash and short-term investments $40.5M at Sept 30, 2022; reaffirms FY2022 revenue $21-22M.","Partner PTC's Upstaza gene therapy approved in EU; SmartFlow Neuro Cannula included in label.","Added ~50 biologics/drug delivery partners; installed record 10 new systems YTD.","FDA cleared ClearPoint Maestro Brain Model, Prism Neuro Laser Therapy, and navigation software v2.1."],"urls":{"canonical":"https://secwatch.observer/filing/0001285550-22-000076","json":"https://secwatch.observer/filing/0001285550-22-000076.json","markdown":"https://secwatch.observer/filing/0001285550-22-000076.md","text":"https://secwatch.observer/filing/0001285550-22-000076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285550/000128555022000076/0001285550-22-000076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285550/000128555022000076/clpt-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:58:54.726372+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"122545552b73a064bed4564a9d06f2e124e53a4e","claim":"ClearPoint Neuro, Inc. reported third quarter ended September 30, 2022 results: revenue $5.1 million. Guidance reaffirmed.","evidence_excerpt":"navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2022. Third Quarter Highlights • Reported quarterly revenue of $5.1 million, a 13% year-over-year increase; • Partner PTC Therapeutics’ gene therapy treatment Upstaza TM was granted full marketing authorization by the European Commission. Upstaza will be","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285550/000128555022000076/0001285550-22-000076-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$5.1 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}